Eculizumab (Soliris®) is a humanized monoclonal antibody (IgG 2/4 kappa immunoglobuline) manufactured in NS0. It is used to treat the rare blood disorder Paroxymal nocturnal haemoglobinuria (a genetically derived disease) which leads to haemolysis of the patients. By binding to the human complement protein C5, it blocks the cleavage of the protein itself which leads to the inhibition of the complement mediated intravascular haemolysis.

To support the analytical development of Eculizumab biosimilars or biobetters, PPS has set up an analysis program in accordance with ICH Q6B guidelines, including method setup, validation of customer-specific methods, and release testing. This package includes different assays for protein quantification, characterizing the protein primary structure  including the slight N- and N-terminal heterogeneity, the glycosylation pattern and the analysis of protein modification


Your contact for Eculizumab at Protagen Protein Services GmbH

Martin-Blueggel 150x100px

Martin Blüggel

Chief Executive Officer (CEO)
Our business development team will be happy to assist you with your project.

Phone: +49 (0) 231 9742-6100